logo
Many UTI hospital admissions could be prevented, according to experts

Many UTI hospital admissions could be prevented, according to experts

Yahoo8 hours ago
One in three hospital trips for urinary tract infections (UTIs) could potentially be avoided, experts have said.
It comes as new data suggests UTIs cost NHS hospitals in England an estimated £604 million in 2023/24.
Admissions increased by 9% during the year compared with the previous 12 months, according to the UK Health Security Agency (UKHSA).
UTIs can affect the bladder, urethra or kidneys, and can include symptoms such as pain while peeing, blood in the pee, and pain in the tummy or back.
The infections are usually caused by bacteria from poo entering the urinary tract.
UKHSA analysis of the Hospital Episode Statistics (HES) database found there were 189,759 hospital admissions relating to UTIs in England in 2023/24.
This resulted in 1.2 million NHS bed days, averaging six bed days per infection.
However, a third of UTI patients were in hospital for less than a day, meaning other treatment options could be considered, according to the UKHSA.
Dr Colin Brown, deputy director at UKHSA responsible for antibiotic resistance, said: 'Urinary tract infections are a major cause of hospitalisations in this country, but many could be prevented.'
The figures also show hospital admissions for UTIs increased up by 9% in 2023/24 compared with the previous year.
However, levels are still below those seen before the Covid-19 pandemic.
More than half of all UTI admissions (52.7%) included in the data were patients aged over 70, and more than six in 10 (61.8%) were women.
Women were nearly five times more likely to need hospital treatment for a UTI in people under the age of 50.
To avoid catching a UTI, experts advise people to drink enough fluid regularly, avoid holding in pee, wash daily, keep the genital areas clean and dry and wipe from front to back when on the toilet to avoid bacteria spreading.
Dr Brown said: 'We know that the most serious consequences that come from UTIs are more common in people over the age of 50 so we are reminding this group in particular to be aware of the ways they can help reduce their risk of getting poorly.
'Drinking enough fluids is so important, as well as avoiding holding onto pee. If you have frequent UTIs, talk to your healthcare provider about treatments that may help prevent further infections.
'If you have a UTI and your symptoms get worse, please call your GP or 111, or go to your nearest A&E, to seek assistance as UTIs can develop into more serious, life-threatening infections.'
Dr Brown also stressed that preventing UTIs is important to tackle antibiotic resistance, as they are often treated with antibiotics.
'Reducing the number of UTI infections means bacteria has less chance to develop this resistance, helping keep antibiotics working for longer,' he said.
Professor Matt Inada-Kim, national clinical director for infections management and antimicrobial resistance at NHS England, said: 'Urinary tract infections are an increasingly common reason for becoming ill at home and in hospitals.
'They are more serious in older patients and, in particular, those with catheters but they can occur at any age and are not often related to poor hygiene.
'Antimicrobial resistance continues to grow and it is vital that we do everything we can to manage urinary infections through prevention, education and providing easy access to healthcare, including diagnostic tests and appropriate treatment.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Weight loss jabs such as Mounjaro linked to lower dementia and stroke risk
Weight loss jabs such as Mounjaro linked to lower dementia and stroke risk

Yahoo

time7 minutes ago

  • Yahoo

Weight loss jabs such as Mounjaro linked to lower dementia and stroke risk

Weight loss jabs may offer a protective effect against dementia and stroke, according to a new study. Academics said the benefits of drugs such as Wegovy and Mounjaro – including for managing weight and blood sugar levels – are well known, but other health benefits of the popular drugs remain 'unclear'. People with type 2 diabetes and obesity who are taking the drugs are also less likely to die prematurely, researchers found. The study saw experts from Taiwan examine date on 60,000 people from around the world, with an average age of 58, who had type 2 diabetes and obesity. Key differences between three weight-loss injections: Mounjaro, Wegovy, and Ozempic. — Paul Wischmeyer MD (@Paul_Wischmeyer) July 4, 2025 Around half were given GLP agonist drugs semaglutide and tirzepatide – which are sold under the brand names Wegovy and Mounjaro. Semaglutide is also the main ingredient for the type 2 diabetes drug Ozempic. GLP agonists can reduce a person's appetite; slow down their digestion; reduce the amount of sugar the liver makes and they help the body to make more insulin when needed. The other half used other anti-diabetic medication. 📢Important update Eligible people in #Dorset will be able to access Tirzepatide (Mounjaro) weight management medication from autumn 2025. ✅Around 1,000 people in Dorset will qualify under strict national criteria ✅No need to contact your doctor More: — NHS Dorset (@NHSDorset) June 23, 2025 During a seven-year follow-up period, researchers found that people given the GLP agonist drugs appeared to have a 37% lower risk of dementia and a 19% reduced risk of stroke. They were also 30% less likely to die during the follow-up period. And when researchers looked at the data further they found even greater benefits in people aged 60 or older, women, and those with a body mass index score of 30 to 40. They found no differences in Parkinson's disease or brain bleeds. The academics said their findings suggest 'potential neuroprotective and cerebrovascular benefits' of the drugs but they called for more studies to confirm the findings. Recommended reading: Mounjaro sales adverts banned by watchdog Mounjaro patients report unexpected side-effect Who is eligible for free Mounjaro on the NHS? 'These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity,' they wrote in the journal JAMA Network Open. Commenting on the study, Professor Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh and group leader in the UK Dementia Research Institute, said: 'This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity. 'This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain. 'It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions. 'Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity.' Recommended reading: When will Mounjaro be rolled out on the NHS? Travel insurance warning about certain types of policy Warning as Mounjaro and Ozempic sold without prescription Dr Richard Oakley, associate director of research and innovation at Alzheimer's Society, said: 'It is well established that diabetes and obesity can increase your risk of developing dementia. 'This study supports existing evidence that shows these drugs may reduce dementia risk, particularly for people aged 60 and over who are living with type 2 diabetes and obesity. 'Although interesting, we can't draw conclusions from this study alone as it is an observational study, only a small number of people who took part went on to develop dementia and as the impact of these drugs on different types of dementia is not clear. 'There are clinical trials currently looking at whether drugs like these can be used to treat early-stage Alzheimer's disease, so this is a really exciting area being explored in the research fight against dementia.'

One in Five Trainee Doctors Fear Escalating Patient Care
One in Five Trainee Doctors Fear Escalating Patient Care

Medscape

time2 hours ago

  • Medscape

One in Five Trainee Doctors Fear Escalating Patient Care

More than one in five trainee doctors in the UK hesitate to escalate concerns about a patient's condition, according to the latest General Medical Council (GMC) national training survey. This figure rose to nearly one in three among trainees in high-pressure specialties, including surgery, obstetrics and gynaecology, general medicine, and emergency medicine. These groups also reported the highest levels of stress, bullying, and incivility. New for 2024, the GMC asked trainees if they ever felt apprehensive about escalating care to a senior colleague. Among those who reported hesitancy: 4% said they felt this daily or weekly. 5% monthly. 12% less often. Professor Pushpinder Mangat, medical director at the GMC, said: "These findings are extremely concerning. Doctors need to feel comfortable escalating concerns. When they don't, there are potentially serious risks to patient safety." Burnout Risk Still High Burnout levels remain high, with one in five trainees at high risk — double the rate reported in 2019, though slightly down from 2023. Burnout varied significantly by specialty – from 30% in emergency medicine to just 4% in public health. Half of the cohort said that they found their work emotionally exhausting to a high or very high degree. Among trainers, 11% were cat high risk of burnout, and 36% at moderate risk. Despite this, 90% said they enjoyed their role, and 70% rated the support they received as either good or very good. Training Quality Mostly Rated Highly The GMC received responses from 50,637 trainees and 21,289 trainers. Among trainees: 87% rated the quality of their clinical supervision as good or very good. 84% said the quality of their training experience was good or very good. 63% said their posts gave them opportunities to develop their leadership skills. However, concerns persisted: 16% of surgery trainees rated teaching quality as poor or very poor, compared with 3% of GP trainees. 61% were at moderate or high risk of burnout. 39% lacked confidence reporting workplace discrimination. 28% experienced negative behaviour from colleagues. 9% of female and 4% of male trainees reported unwelcome sexual comments or advances. Rota Gaps The survey also found continuing problems due to rota gaps, with 26% saying their training had been affected because these gaps are not being dealt with effectively. The GMC said it is 'vital' that trusts and boards address the issue. The report noted a steady increase over recent years in the proportion of trainees working less than full time, which now involved 30% of female and 15% of male trainees. There was also 'notable variation' between specialties, with 46% of paediatrics and child health trainees training less than full time, compared with just 8% of those in surgery posts. Those rating their workload as heavy or very heavy (42% overall) ranged from 70% in emergency medicine to 19% in public health. Of those who worked less than full-time, or had considered or applied to do so, 66% sought a better work-life balance and 44% cited childcare responsibilities. The GMC called for flexible training models to create a sustainable workforce and safe patient care. It was 'clear that medical education and training needs to adapt', it said.

Hidden health benefits from weight-loss shots revealed
Hidden health benefits from weight-loss shots revealed

Yahoo

time2 hours ago

  • Yahoo

Hidden health benefits from weight-loss shots revealed

Weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer a protective shield against serious conditions such as dementia and stroke, a new study has indicated. The research also suggests that individuals with type 2 diabetes and obesity who are prescribed these medications could face a reduced risk of premature death. Academics behind the study noted that while the efficacy of GLP agonist drugs – such as semaglutide (found in Wegovy and Ozempic) and tirzepatide (Mounjaro) – in managing weight and blood sugar levels is widely recognised, their wider health benefits have remained less understood. The comprehensive study, conducted by experts in Taiwan, examined data from 60,000 people worldwide, with an average age of 58, all diagnosed with type 2 diabetes and obesity. Roughly half of the participants were given GLP agonist drugs. These medications function by curbing appetite, slowing digestion, reducing the liver's sugar output, and enhancing the body's insulin production when required. The other half used other anti-diabetic medication. During a seven-year follow-up period, researchers found that people given the GLP agonist drugs appeared to have a 37 per cent lower risk of dementia and a 19 per cent reduced risk of stroke. Weight-loss drugs like Wegovy are available on the NHS to obese patients They were also 30 per cent less likely to die during the follow-up period. When researchers looked at the data further, they found even greater benefits in people aged 60 or older, women, and those with a body mass index score of 30 to 40. They found no differences in Parkinson's disease or brain bleeds. The academics said their findings suggest 'potential neuroprotective and cerebrovascular benefits' of the drugs but they called for more studies to confirm the findings. 'These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity,' they wrote in the journal JAMA Network Open. Commenting on the study, Professor Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh and group leader in the UK Dementia Research Institute, said: 'This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity. 'This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain. 'It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions. 'Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store